{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:18:47Z","timestamp":1792703927740,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-06151-w","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:10:35Z","timestamp":1765800635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review of gene-mediated therapy in BCG-unresponsive NMIBC: emerging evidence and future perspectives"],"prefix":"10.1007","volume":"44","author":[{"given":"Constance","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idir","family":"Ouzaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Etienne","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"6","key":"6151_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM et al (2018) Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 74(6):784\u2013795","journal-title":"Eur Urol"},{"issue":"6","key":"6151_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F et al (2024) European association of urology guidelines on Non-muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)-A summary of the 2024 guidelines update. Eur Urol 86(6):531\u2013549","journal-title":"Eur Urol"},{"issue":"7","key":"6151_CR3","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/cancers16071366","volume":"16","author":"M Jaromin","year":"2024","unstructured":"Jaromin M, Konecki T, Kutwin P (2024) Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. Cancers 16(7):1366","journal-title":"Cancers"},{"issue":"5","key":"6151_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Mart\u00ednez-Pi\u00f1eiro L, Babjuk MM et al (2020) Treatment of High-grade Non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European association of urology research foundation randomised phase III clinical trial \u00ab\u202fNIMBUS\u202f\u00bb. Eur Urol 78(5):690\u2013698","journal-title":"Eur Urol"},{"issue":"1","key":"6151_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158(1):62\u201367","journal-title":"J Urol"},{"issue":"4","key":"6151_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.euo.2018.10.008","volume":"2","author":"R Satkunasivam","year":"2019","unstructured":"Satkunasivam R, Tallman CT, Taylor JM, Miles BJ, Klaassen Z, Wallis CJD (2019) Robot-assisted radical cystectomy versus open radical cystectomy: A Meta-analysis of Oncologic, Perioperative, and Complication-related outcomes. Eur Urol Oncol 2(4):443\u2013447","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"6151_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.urology.2009.05.087","volume":"74","author":"BK Somani","year":"2009","unstructured":"Somani BK, Gimlin D, Fayers P, N\u2019dow J (2009) Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion--a prospective cohort study with a systematic review of literature. Urology 74(5):1138\u20131143","journal-title":"Urology"},{"key":"6151_CR8","doi-asserted-by":"publisher","DOI":"10.23736\/S2241-9136.25.00080-5","author":"P-E Gabriel","year":"2025","unstructured":"Gabriel P-E, Ouzaid I, Prad\u00e8re B, Roumigui\u00e9 M, Moschini M (2025) Shariat S et al Emerging evidence of immunotherapy in BCG-unresponsive non-muscle invasive bladder cancer. Hell Urol. https:\/\/doi.org\/10.23736\/S2241-9136.25.00080-5","journal-title":"Hell Urol"},{"issue":"6","key":"6151_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/MOU.0000000000001343","volume":"35","author":"PE Gabriel","year":"2025","unstructured":"Gabriel PE, Horowitz A, Sfakianos JP, Xylinas E (2025) Targeted therapies for Bacillus Calmette-Gu\u00e9rin unresponsive nonmuscle-invasive bladder cancer: a narrative review. Curr Opin Urol 35(6):661\u2013665","journal-title":"Curr Opin Urol"},{"key":"6151_CR10","doi-asserted-by":"crossref","unstructured":"Daneshmand S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, B\u00f6gemann M, Simone G et al (2025) TAR-200 for Bacillus Calmette-Gu\u00e9rin-Unresponsive High-Risk Non-Muscle-Invasive bladder cancer: results from the phase IIb SunRISe-1 study. J Clin Oncol Off J Am Soc Clin Oncol, p JCO2501651.","DOI":"10.1200\/JCO-25-02053"},{"issue":"5","key":"6151_CR11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/JU.0000000000000688","volume":"203","author":"RL Steinberg","year":"2020","unstructured":"Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T et al (2020) Multi-Institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 203(5):902\u2013909","journal-title":"J Urol"},{"issue":"1","key":"6151_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","volume":"66","author":"RJ Connor","year":"2005","unstructured":"Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H (2005) Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 66(1):224\u2013229","journal-title":"Urology"},{"issue":"3","key":"6151_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","volume":"10","author":"WF Benedict","year":"2004","unstructured":"Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L et al (2004) Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 10(3):525\u201332","journal-title":"Mol Ther"},{"key":"6151_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1359725","volume":"14","author":"VM Narayan","year":"2024","unstructured":"Narayan VM, Meeks JJ, Jakobsen JS, Shore ND, Sant GR, Konety BR (2024) Mechanism of action of nadofaragene firadenovec-vncg. Front Oncol 14:1359725","journal-title":"Front Oncol"},{"issue":"3","key":"6151_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"CPN Dinney","year":"2013","unstructured":"Dinney CPN, Fisher MB, Navai N, O\u2019Donnell MA, Cutler D, Abraham A et al (2013) Phase I trial of intravesical Recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer. J Urol 190(3):850\u2013856","journal-title":"J Urol"},{"issue":"12","key":"6151_CR16","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1245\/s10434-016-5300-6","volume":"23","author":"N Navai","year":"2016","unstructured":"Navai N, Benedict WF, Zhang G, Abraham A, Ainslie N, Shah JB et al (2016) Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon \u03b12b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol 23(12):4110\u20134","journal-title":"Ann Surg Oncol"},{"issue":"30","key":"6151_CR17","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","volume":"35","author":"ND Shore","year":"2017","unstructured":"Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM et al (2017) Intravesical rAd-IFN\u03b1\/Syn3 for patients with High-Grade, Bacillus Calmette-Guerin-Refractory or relapsed Non-Muscle-Invasive bladder cancer: A phase II randomized study. J Clin Oncol Off J Am Soc Clin Oncol 35(30):3410\u20133416","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"6151_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM et al (2021) Intravesical nadofaragene Firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107\u2013117","journal-title":"Lancet Oncol"},{"issue":"1","key":"6151_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/JU.0000000000004020","volume":"212","author":"VM Narayan","year":"2024","unstructured":"Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG et al (2024) Efficacy of intravesical nadofaragene Firadenovec for patients with Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle-Invasive bladder cancer: 5-Year Follow-Up from a phase 3 trial. J Urol 212(1):74\u201386","journal-title":"J Urol"},{"issue":"1","key":"6151_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S et al (2006) CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res Off J Am Assoc Cancer Res 12(1):305\u2013313","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"6151_CR21","unstructured":"Cretostimogene Grenadenorepvec At the CORE and Forming BONDs in High-Risk NMIBC and PIVOTing into Intermediate Risk NMIBC [Internet]. [cit\u00e9 29 sept 2025]. Disponible sur: https:\/\/www.urotoday.com\/library-resources\/bladder-cancer\/148370-cretostimogene-grenadenorepvec-at-the-core-and-forming-bonds-in-high-risk-nmibc-and-pivoting-into-intermediate-risk-nmibc.html"},{"issue":"6","key":"6151_CR22","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"JM Burke","year":"2012","unstructured":"Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC et al (2012) A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 188(6):2391\u20132397","journal-title":"J Urol"},{"issue":"10","key":"6151_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL et al (2018) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol 36(10):440\u2013447","journal-title":"Urol Oncol"},{"key":"6151_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.02","author":"MD Tyson","year":"2025","unstructured":"Tyson MD, Uchio EM, Nam JK, Joshi SS, Bivalacqua TJ, Steinberg GD et al (2025) Final results: bond-003 cohort c- phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. J Urol. https:\/\/doi.org\/10.1097\/01.JU.0001111604.90306.91.02","journal-title":"J Urol"},{"key":"6151_CR25","unstructured":"TechBear (2025) CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting [Internet]. CG Oncology |. [cit\u00e9 29 sept 2025]. Disponible sur: https:\/\/cgoncology.com\/cg-oncology-announces-bond-003-topline-results-aua-2025\/"},{"issue":"7","key":"6151_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumigui\u00e9 M et al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22(7):919\u2013930","journal-title":"Lancet Oncol"},{"issue":"8","key":"6151_CR27","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","volume":"30","author":"R Li","year":"2024","unstructured":"Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL et al (2024) Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med 30(8):2216\u20132223","journal-title":"Nat Med"},{"key":"6151_CR28","unstructured":"A phase 1\/2 study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. - EAU 2025 [Internet]. [cit\u00e9 8 oct 2025]. Disponible sur: https:\/\/www.urotoday.com\/conference-highlights\/eau-2025\/eau-2025-bladder-cancer\/159126-eau-2025-a-phase-1-2-study-of-detalimogene-voraplasmid-eg-70-intravesical-monotherapy-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-trial-in-progr"},{"issue":"5_suppl","key":"6151_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1200\/JCO.2025.43.5_suppl.802","volume":"43","author":"JA Taylor","year":"2025","unstructured":"Taylor JA, Joshi S, Satkunasivam R, Dickstein RJ, Salmasi A, Lotan Y et al (2025) Preliminary results from LEGEND: a phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). J Clin Oncol 43(5_suppl):802\u2013802. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.802","journal-title":"J Clin Oncol"},{"issue":"4","key":"6151_CR30","doi-asserted-by":"publisher","first-page":"e043266","DOI":"10.1136\/bmjopen-2020-043266","volume":"11","author":"SL Maibom","year":"2021","unstructured":"Maibom SL, Joensen UN, Poulsen AM, Kehlet H, Brasso K, R\u00f8der MA (2021) Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open 11(4):e043266","journal-title":"BMJ Open"},{"issue":"2","key":"6151_CR31","doi-asserted-by":"publisher","first-page":"e471942","DOI":"10.1200\/EDBK-25-471942","volume":"45","author":"M Filon","year":"2025","unstructured":"Filon M, Schmidt B (2025) New treatment options for Non-Muscle-Invasive bladder cancer. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 45(2):e471942","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"6151_CR32","doi-asserted-by":"crossref","unstructured":"Taylor JI, Kamat AM, O\u2019Donnell MA, Annapureddy D, Howard J, Tan WS et al (2025) Long-term outcomes of bladder\u2010sparing therapy vs radical cystectomy in BCG\u2010unresponsive non\u2010muscle\u2010invasive bladder cancer. Bju Int [Internet] 135(2):260\u2013268. Disponible sur: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11745998\/","DOI":"10.1111\/bju.16509"},{"issue":"19","key":"6151_CR33","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","volume":"29","author":"R Li","year":"2023","unstructured":"Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G et al (2023) A phase II study of durvalumab for Bacillus Calmette-Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder. Clin Cancer Res Off J Am Assoc Cancer Res 29(19):3875\u20133881","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"6151_CR34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","volume":"84","author":"PC Black","year":"2023","unstructured":"Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT et al (2023) Phase 2 trial of Atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive High-risk Non-muscle-invasive bladder cancer: SWOG S1605. Eur Urol 84(6):536\u2013544","journal-title":"Eur Urol"},{"issue":"8","key":"6151_CR35","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","volume":"25","author":"K Fukumoto","year":"2018","unstructured":"Fukumoto K, Kikuchi E, Mikami S, Hayakawa N, Matsumoto K, Niwa N et al (2018) Clinical role of programmed cell Death-1 expression in patients with Non-muscle-invasive bladder cancer recurring after initial Bacillus Calmette-Gu\u00e9rin therapy. Ann Surg Oncol 25(8):2484\u20132491","journal-title":"Ann Surg Oncol"},{"key":"6151_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.10.030","volume":"41","author":"PT Chevuru","year":"2023","unstructured":"Chevuru PT, McElree IM, Mott SL, Steinberg RL, O\u2019Donnell MA, Packiam VT (2023) Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urol Oncol 41:148.e1-148.e7","journal-title":"Urol Oncol"},{"key":"6151_CR37","doi-asserted-by":"publisher","first-page":"458.e1","DOI":"10.1016\/j.urolonc.2023.06.018","volume":"41","author":"K Yim","year":"2023","unstructured":"Yim K, Melnick K, Mott SL, Carvalho FLF, Zafar A, Clinton TN et al (2023) Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol Oncol 41:458.e1-458.e7","journal-title":"Urol Oncol"},{"key":"6151_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","volume":"8","author":"J Taylor","year":"2025","unstructured":"Taylor J, Kamat AM, Annapureddy D, Khene Z-E, Howard J, Tan WS et al (2025) Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Gu\u00e9rin in patients with Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer. Eur Urol Oncol 8:469\u201376","journal-title":"Eur Urol Oncol"},{"key":"6151_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/BLC-170126","volume":"3","author":"N Milbar","year":"2017","unstructured":"Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T, Sankin A et al (2017) Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer 3:293\u2013303","journal-title":"Bladder Cancer"},{"key":"6151_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/BLC-150008","volume":"1","author":"RL Steinberg","year":"2015","unstructured":"Steinberg RL, Thomas LJ, O\u2019Donnell MA, Nepple KG (2015) Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer Amst Neth 1:65\u201372","journal-title":"Bladder Cancer Amst Neth"},{"key":"6151_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.07.022","volume":"38","author":"MJ Daniels","year":"2020","unstructured":"Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ, Sankin A et al (2020) An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer. Urol Oncol 38:40.e17-40.e24","journal-title":"Urol Oncol"},{"issue":"6","key":"6151_CR42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bju.16645","volume":"135","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D et al (2025) Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. BJU Int 135(6):969\u2013976","journal-title":"BJU Int"},{"issue":"6","key":"6151_CR43","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/MOU.0000000000001329","volume":"35","author":"F Guerrero-Ramos","year":"2025","unstructured":"Guerrero-Ramos F, G\u00f3mez-Ca\u00f1izo C, Hern\u00e1ndez-Arroyo M, Subiela JD, Pradere B, Xylinas E (2025) Hyperthermic intravesical chemotherapy for Bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer. Curr Opin Urol 35(6):620\u20138","journal-title":"Curr Opin Urol"},{"key":"6151_CR44","doi-asserted-by":"crossref","unstructured":"Vilaseca A, Jayram G, Raventos C, Shore ND, Zainfeld D, Kang TW, et al (2024) First safety and afficacy results of TAR-210 Erdafitinib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations. J Urol","DOI":"10.1016\/S0302-2838(24)01169-2"},{"key":"6151_CR45","doi-asserted-by":"crossref","unstructured":"Narayan VM, Tholomier C, Mokkapati S, Martini A, Caruso VM, Goudarzi M et al (2025) Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Non\u2013muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec. Eur Urol Oncol [Internet] 8(2):425\u201334. Disponible sur: https:\/\/euoncology.europeanurology.com\/article\/S2588-9311(24)00225-6\/fulltext","DOI":"10.1016\/j.euo.2024.09.016"},{"key":"6151_CR46","unstructured":"ICER Issues Correction to Final Evidence Report on New Therapies for Bladder Cancer [Internet] ICER. https:\/\/icer.org\/news-insights\/press-releases\/icer-issues-correction-to-final-evidence-report-on-new-therapies-for-bladder-cancer\/"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06151-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-06151-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06151-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:10:39Z","timestamp":1765800639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-06151-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6151"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-06151-w","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"44"}}